Your session is about to expire
← Back to Search
Special Shoes for Peripheral Arterial Disease (PAD Trial)
N/A
Waitlist Available
Led By Hafizur Rahman, PhD
Research Sponsored by VA Office of Research and Development
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and after three-months intervention
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing special shoes for patients with PAD to help them walk better and with less pain. The shoes provide an extra boost with each step, which can improve mobility and quality of life for these patients.
Who is the study for?
This trial is for individuals who can consent, have chronic leg pain during exercise due to PAD with an ankle brachial index below 0.90, and stable blood pressure, cholesterol, and diabetes management. It's not for those with severe PAD causing rest pain or tissue loss, recent ischemic events in the legs from clots or trauma, or walking issues caused by other health problems.
What is being tested?
The study tests special assistive tennis shoes designed for people with Peripheral Artery Disease (PAD) to see if they help reduce pain and increase physical activity compared to standard shoes. The goal is to improve daily living activities and potentially decrease related health risks.
What are the potential side effects?
Since this trial involves using specially designed shoes rather than medication, typical drug side effects are not expected. However, participants may experience discomfort or skin irritation specific to the fit and design of the assistive shoes.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline and after three-months intervention
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and after three-months intervention
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Changes in walking distance after three-months intervention
Comfort level of wearing assistive shoe expressed as a numeric value and this value will be rated by participants
Secondary study objectives
Changes in Walking Impairment Questionnaire score after three-months intervention
Changes in muscle oxygenation after three-months intervention
Changes in physical activity after three-months intervention
+1 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Progressive improvement in walking performanceExperimental Treatment1 Intervention
A total of ten patients with peripheral artery disease will be enrolled for this arm and wear the assistive tennis shoes for three-months as an intervention.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Peripheral Arterial Disease (PAD) treatments focus on improving blood flow and reducing pain to enhance physical activity. Exercise therapy, especially supervised walking programs, is essential as it promotes vascular health and increases blood flow to the legs.
Assistive devices, such as specially designed shoes, support this by reducing pain and encouraging more physical activity. This combination helps improve circulation, reduce claudication symptoms, and enhance the overall quality of life for PAD patients.
Exercise rehabilitation for patients with peripheral arterial disease.Effect of high-pain versus low-pain structured exercise on walking ability in people with intermittent claudication: meta-analysis.[Short and medium term functional capacity after single cycle of controlled physical training in subjects with claudication].
Exercise rehabilitation for patients with peripheral arterial disease.Effect of high-pain versus low-pain structured exercise on walking ability in people with intermittent claudication: meta-analysis.[Short and medium term functional capacity after single cycle of controlled physical training in subjects with claudication].
Find a Location
Who is running the clinical trial?
VA Office of Research and DevelopmentLead Sponsor
1,668 Previous Clinical Trials
3,765,855 Total Patients Enrolled
13 Trials studying Peripheral Arterial Disease
1,418 Patients Enrolled for Peripheral Arterial Disease
University of NebraskaOTHER
555 Previous Clinical Trials
1,145,375 Total Patients Enrolled
14 Trials studying Peripheral Arterial Disease
565 Patients Enrolled for Peripheral Arterial Disease
Hafizur Rahman, PhDPrincipal InvestigatorOmaha VA Nebraska-Western Iowa Health Care System, Omaha, NE
Sara A. Myers, PhDPrincipal InvestigatorOmaha VA Nebraska-Western Iowa Health Care System, Omaha, NE
1 Previous Clinical Trials
47 Total Patients Enrolled
1 Trials studying Peripheral Arterial Disease
47 Patients Enrolled for Peripheral Arterial Disease
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have severe leg pain or tissue loss due to poor blood flow.I recently had a blood clot or injury affecting my leg.My blood pressure, cholesterol, and diabetes treatments have been stable for 6 weeks.Your ankle brachial index at rest is less than 0.90.You have a history of chronic leg pain while walking.My ability to walk is limited due to conditions not related to leg pain from walking.
Research Study Groups:
This trial has the following groups:- Group 1: Progressive improvement in walking performance
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.